MARSHALL WACE, LLP - BRIDGEBIO PHARMA INC ownership

BRIDGEBIO PHARMA INC's ticker is BBIO and the CUSIP is 10806X102. A total of 182 filers reported holding BRIDGEBIO PHARMA INC in Q1 2022. The put-call ratio across all filers is 0.50 and the average weighting 0.3%.

Quarter-by-quarter ownership
MARSHALL WACE, LLP ownership history of BRIDGEBIO PHARMA INC
ValueSharesWeighting
Q3 2023$4,296,094
-76.1%
162,916
-85.0%
0.01%
-76.3%
Q1 2023$17,982,585
+2439.9%
1,084,595
+1422.3%
0.04%
+1800.0%
Q3 2022$708,000
-85.4%
71,245
-75.5%
0.00%
-77.8%
Q4 2021$4,843,000
+566.2%
290,362
+1771.0%
0.01%
+200.0%
Q3 2021$727,000
-84.5%
15,519
-79.6%
0.00%
-85.7%
Q1 2021$4,681,00075,9950.02%
Other shareholders
BRIDGEBIO PHARMA INC shareholders Q1 2022
NameSharesValueWeighting ↓
Aisling Capital Management LP 6,068,125$160,016,45665.94%
Kohlberg Kravis Roberts & Co. L.P. 31,060,971$819,077,80528.79%
Cormorant Asset Management, LP 4,662,530$122,950,9167.17%
Frazier Life Sciences Management, L.P. 2,725,949$71,883,2754.77%
Octagon Capital Advisors LP 971,639$25,622,1203.94%
M28 Capital Management LP 121,200$3,196,0443.66%
VIKING GLOBAL INVESTORS LP 25,120,991$662,440,5332.69%
BOONE CAPITAL MANAGEMENT LLC 313,381$8,263,8572.61%
Fernwood Investment Management, LLC 235,620$6,213,2992.23%
SOUTHPORT MANAGEMENT, L.L.C. 15,000$395,5502.15%
View complete list of BRIDGEBIO PHARMA INC shareholders